United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug (nsaid) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). diclofenac sodium topical solution, usp is contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product [see warnings and precautions (5.7, 5.9)]. - history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients [ see warnings and precautions (5.7, 5.8) ] . - in the setting of coronary artery bypass graft (cabg) surgery [ see warnings and precautions (5.1) ]. risk summary use of nsaids, including diclofenac sodium, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal rena

Australia - English - Department of Health (Therapeutic Goods Administration)

church and dwight australia pty ltd - equisetum arvense, quantity: 45 mg (equivalent: equisetum arvense, qty 247.5 mg); ferrous fumarate, quantity: 31.95 mg (equivalent: iron, qty 10.51 mg); zinc oxide, quantity: 14.01 mg (equivalent: zinc, qty 11.208 mg); biotin, quantity: 120 microgram; panicum miliaceum, quantity: 7.5 mg (equivalent: panicum miliaceum, qty 142.5 mg); malpighia glabra, quantity: 8.8 mg (equivalent: ascorbic acid, qty 1.5 mg); ascorbic acid, quantity: 57.39 mg; nicotinamide, quantity: 12.06 mg; shark cartilage, quantity: 374.9 - tablet, film coated - excipient ingredients: croscarmellose sodium; silicon dioxide; hypromellose; magnesium stearate; maltodextrin; glycerol; microcrystalline cellulose; colloidal anhydrous silica; flavour; oyster - aid/assist/help/maintain healthy hair follicles ; maintain/support hair growth ; enhance/improve/promote/increase hair growth ; maintain/support hair health ; enhance/improve/promote/increase hair health ; enhance/improve/promote/increase hair strength/thickness ; maintain/support hair strength/thickness ; decrease/reduce hair loss/thinning

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rotop radiopharmacy gmbh - sodium iodide (123 i) 74 mbq/ml - solution for injection - 74 mbq/ml - ioflupane (i-123) 74 mbq/ml - iodine ioflupane (123i)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

rotop radiopharmacy gmbh - sodium iodide (123 i) 74 mbq/ml - solution for injection - 74 mbq/ml - ioflupane (i-123) 74 mbq/ml - iodine ioflupane (123i)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - megestrol acetate - oral tablet - megestrol acetate steroid-progestin active 20.0 mg/tb - endocrine system - cat | dog | dog - female (bitch) | bitch | castrate | cat - queen | cat - tom | kitten | puppy - eosinophilic granulomas | improving behaviour | mammary tumours | miliary eczema | modify hypersexuality | postpone oestrus | prevent oestrus | pseudo-pregnancy | urine spray | eliminate urine spraying | excess libido - reduce | pseudo-cyesis | pseudo-pregnancy lactation

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

intervet australia pty limited - megestrol acetate - oral tablet - megestrol acetate steroid-progestin active 5.0 mg/tb - endocrine system - cat | dog | dog - female (bitch) | bitch | castrate | cat - queen | cat - tom | kitten | puppy - eosinophilic granulomas | improving behaviour | mammary tumours | miliary eczema | modify hypersexuality | postpone oestrus | prevent oestrus | pseudo-pregnancy | urine spray | eliminate urine spraying | excess libido - reduce | pseudo-cyesis | pseudo-pregnancy lactation

Israel - English - Ministry of Health

organon pharma israel ltd., israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - ezetimibe - primary hypercholesterolemia: ezetrol administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetrol administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezetrol are indicated for use in patients with homozygous familial sitosterolemia.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - canakinumab - cryopyrin-associated periodic syndromes; arthritis, juvenile rheumatoid; arthritis, gouty - interleukin inhibitors, - periodic fever syndromesilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:cryopyrin-associated periodic syndromesilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (caps) including:muckle-wells syndrome (mws),neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca),severe forms of familial cold autoinflammatory syndrome (fcas) / familial cold urticaria (fcu) presenting with signs and symptoms beyond cold-induced urticarial skin rash.tumour necrosis factor receptor associated periodic syndrome (traps)ilaris is indicated for the treatment of tumour necrosis factor (tnf) receptor associated periodic syndrome (traps).hyperimmunoglobulin d syndrome (hids)/mevalonate kinase deficiency (mkd)ilaris is indicated for the treatment of hyperimmunoglobulin d syndrome (hids)/mevalonate kinase deficiency (mkd).familial mediterranean fever (fmf)ilaris is indicated for the treatment of familial mediterranean fever (fmf). ilaris should be given in combination with colchicine, if appropriate.ilaris is also indicated for the treatment of:still’s diseaseilaris is indicated for the treatment of active still’s disease including adult-onset still’s disease (aosd) and systemic juvenile idiopathic arthritis (sjia) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (nsaids) and systemic corticosteroids. ilaris can be given as monotherapy or in combination with methotrexate.gouty arthritisilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (nsaids) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

European Union - English - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - anakinra - arthritis, rheumatoid; covid-19 virus infection - immunosuppressants - rheumatoid arthritis (ra)kineret is indicated in adults for the treatment of the signs and symptoms of ra in combination with methotrexate, with an inadequate response to methotrexate alone.covid-19kineret is indicated for the treatment of coronavirus disease 2019 (covid-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (supar) ≥ 6 ng/ml.periodic fever syndromeskineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:cryopyrin-associated periodic syndromes (caps)kineret is indicated for the treatment of caps, including:neonatal-onset multisystem inflammatory disease (nomid) / chronic infantile neurological, cutaneous, articular syndrome (cinca)muckle-wells syndrome (mws)familial cold autoinflammatory syndrome (fcas)familial mediterranean fever (fmf)kineret is indicated for the treatment of familial mediterranean fever (fmf). kineret should be given in combination with colchicine, if appropriate.still’s diseasekineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of still’s disease, including systemic juvenile idiopathic arthritis (sjia) and adult-onset still’s disease (aosd), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (nsaids) or glucocorticoids.kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (dmards).

European Union - English - EMA (European Medicines Agency)

amryt pharmaceuticals dac - lomitapide - hypercholesterolemia - lipid modifying agents - lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (ldl) apheresis in adult patients with homozygous familial hypercholesterolaemia (hofh). genetic confirmation of hofh should be obtained whenever possible. other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,